Antitumor effect of novel anti-podoplanin antibody NZ-12 against malignant pleural mesothelioma in an orthotopic xenograft model

Cancer Science

Volumn 107, Issue 9, 2016, Pages 1198-1205

  Abe, Shinji ^a   Kaneko, Mika Kato ^b   Tsuchihashi, Yuki ^a   Izumi, Toshihiro ^a   Ogasawara, Satoshi ^b   Okada, Naoto ^a   Sato, Chiemi ^a   Tobiume, Makoto ^a   Otsuka, Kenji ^a   Miyamoto, Licht ^a   Tsuchiya, Koichiro ^a   Kawazoe, Kazuyoshi ^a   Kato, Yukinari ^b   Nishioka, Yasuhiko ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

antibody dependent cellular cytotoxicity; mesothelioma; NZ 12; orthotopic xenograft model; podoplanin

Indexed keywords

ANTINEOPLASTIC AGENT; CD56 ANTIGEN; CHIMERIC ANTIBODY; MONOCLONAL ANTIBODY; NZ 1 ANTIBODY; NZ 12 ANTIBODY; NZ 8 ANTIBODY; PEMETREXED; PODOPLANIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; EFFECTOR CELL; HUMAN; HUMAN CELL; INTRATHORACIC DRUG ADMINISTRATION; MALE; MONONUCLEAR CELL; MOUSE; NATURAL KILLER CELL; NONHUMAN; PLEURA EFFUSION; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; RAT; SPLEEN CELL; THORAX TUMOR; TUMOR XENOGRAFT;

EID: 84987621334     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12985     Document Type: Article

References (39)

1. Breiteneder-Geleff S, Matsui K, Soleiman A et al. Podoplanin, novel 43-kd membrane protein of glomerular epithelial cells, is down-regulated in puromycin nephrosis. Am J Pathol 1997; 151: 1141–52.
2. Breiteneder-Geleff S, Soleiman A, Kowalski H et al. Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am J Pathol 1999; 154: 385–94.
3. Vanderbilt JN, Allen L, Gonzalez RF et al. Directed expression of transgenes to alveolar type I cells in the mouse. Am J Respir Cell Mol Biol 2008; 39: 253–62.
4. Kato Y, Fujita N, Kunita A et al. Molecular identification of Aggrus/T1alpha as a platelet aggregation-inducing factor expressed in colorectal tumors. J Biol Chem 2003; 278: 51599–605.
5. Kato Y, Sasagawa I, Kaneko M, Osawa M, Fujita N, Tsuruo T. Aggrus: a diagnostic marker that distinguishes seminoma from embryonal carcinoma in testicular germ cell tumors. Oncogene 2004; 23: 8552–6.
6. Kato Y, Kaneko M, Sata M, Fujita N, Tsuruo T, Osawa M. Enhanced expression of Aggrus (T1alpha/podoplanin), a platelet-aggregation-inducing factor in lung squamous cell carcinoma. Tumour Biol 2005; 26: 195–200.
7. Mishima K, Kato Y, Kaneko MK, Nishikawa R, Hirose T, Matsutani M. Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression. Acta Neuropathol 2006; 111: 483–8.
8. Kato Y, Vaidyanathan G, Kaneko MK et al. Evaluation of anti-podoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomas. Nucl Med Biol 2010; 37: 785–94.
9. Abe S, Morita Y, Kaneko MK et al. A novel targeting therapy of malignant mesothelioma using anti-podoplanin antibody. J Immunol 2013; 190: 6239–49.
10. Kaneko MK, Kato Y, Kitano T, Osawa M. Conservation of a platelet activating domain of Aggrus/podoplanin as a platelet aggregation-inducing factor. Gene 2006; 378: 52–7.
11. Kawase A, Ishii G, Nagai K et al. Podoplanin expression by cancer associated fibroblasts predicts poor prognosis of lung adenocarcinoma. Int J Cancer 2008; 123: 1053–9.
12. Hoshino A, Ishii G, Ito T et al. Podoplanin-positive fibroblasts enhance lung adenocarcinoma tumor formation: podoplanin in fibroblast functions for tumor progression. Cancer Res 2011; 71: 4769–79.
13. Schoppmann SF, Jesch B, Riegler MF et al. Podoplanin expressing cancer associated fibroblasts are associated with unfavourable prognosis in adenocarcinoma of the esophagus. Clin Exp Metastasis 2013; 30: 441–6.
14. Shindo K, Aishima S, Ohuchida K et al. Podoplanin expression in cancer-associated fibroblasts enhances tumor progression of invasive ductal carcinoma of the pancreas. Mol Cancer 2013; 12: 168.
15. Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005; 353: 1591–603.
16. Pelucchi C, Malvezzi M, La Vecchia C, Levi F, Decarli A, Negri E. The Mesothelioma epidemic in Western Europe: an update. Br J Cancer 2004; 90: 1022–4.
17. Murayama T, Takahashi K, Natori Y, Kurumatani N. Estimation of future mortality from pleural malignant mesothelioma in Japan based on an age-cohort model. Am J Ind Med 2006; 49: 1–7.
18. Ray M, Kindler HL. Malignant pleural mesothelioma: an update on biomarkers and treatment. Chest 2009; 136: 888–96.
19. Scherpereel A, Astoul P, Baas P et al. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J 2010; 35: 479–95.
20. Vogelzang NJ, Rusthoven JJ, Symanowski J et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21: 2636–44.
21. Li Q, Wang W, Machino Y et al. Therapeutic activity of glycoengineered anti-GM2 antibodies against malignant pleural mesothelioma. Cancer Sci 2015; 106: 102–7.
22. Hassan R, Cohen SJ, Phillips M et al. Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers. Clin Cancer Res 2010; 16: 6132–8.
23. Jiang XR, Song A, Bergelson S et al. Advances in the assessment and control of the effector functions of therapeutic antibodies. Nat Rev Drug Discov 2011; 10: 101–11.
24. Kato Y, Kaneko MK, Kuno A et al. Inhibition of tumor cell-induced platelet aggregation using a novel anti-podoplanin antibody reacting with its platelet-aggregation-stimulating domain. Biochem Biophys Res Commun 2006; 349: 1301–7.
25. Ogasawara S, Kaneko MK, Price JE, Kato Y. Characterization of anti-podoplanin monoclonal antibodies: critical epitopes for neutralizing the interaction between podoplanin and CLEC-2. Hybridoma (Larchmt) 2008; 27: 259–67.
26. Kato Y, Kaneko MK, Kunita A et al. Molecular analysis of the pathophysiological binding of the platelet aggregation-inducing factor podoplanin to the C-type lectin-like receptor CLEC-2. Cancer Sci 2008; 99: 54–61.
27. Kaneko MK, Kunita A, Abe S et al. Chimeric anti-podoplanin antibody suppresses tumor metastasis through neutralization and antibody-dependent cellular cytotoxicity. Cancer Sci 2012; 103: 1913–9.
28. Kawaguchi K, Murakami H, Taniguchi T et al. Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells. Carcinogenesis 2009; 30: 1097–105.
29. Wang W, Nishioka Y, Ozaki S et al. HM1.24 (CD317) is a novel target against lung cancer for immunotherapy using anti-HM1.24 antibody. Cancer Immunol Immunother 2009; 58: 967–76.
30. Kishuku M, Nishioka Y, Abe S et al. Expression of soluble vascular endothelial growth factor receptor-1 in human monocyte-derived mature dendritic cells contributes to their antiangiogenic property. J Immunol 2009; 183: 8176–85.
31. Kato Y, Kunita A, Abe S et al. The chimeric antibody chLpMab-7 targeting human podoplanin suppresses pulmonary metastasis via ADCC and CDC rather than via its neutralizing activity. Oncotarget 2015; 6: 36003–18.
32. Wang W, Nishioka Y, Ozaki S et al. Chimeric and humanized anti-HM1.24 antibodies mediate antibody-dependent cellular cytotoxicity against lung cancer cells. Lung Cancer 2009; 63: 23–31.
33. Li Q, Yano S, Ogino H et al. The therapeutic efficacy of anti vascular endothelial growth factor antibody, bevacizumab, and pemetrexed against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice. Clin Cancer Res 2007; 13: 5918–25.
34. Ikuta K, Yano S, Trung VT et al. E7080, a multi-tyrosine kinase inhibitor, suppresses the progression of malignant pleural mesothelioma with different proangiogenic cytokine production profiles. Clin Cancer Res 2009; 15: 7229–37.
35. Nakataki E, Yano S, Matsumori Y et al. Novel orthotopic implantation model of human malignant pleural mesothelioma (EHMES-10 cells) highly expressing vascular endothelial growth factor and its receptor. Cancer Sci 2006; 97: 183–91.
36. Van TT, Hanibuchi M, Kakiuchi S et al. The therapeutic efficacy of S-1 against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice. Cancer Chemother Pharmacol 2011; 68: 497–504.
37. Shevchenko I, Karakhanova S, Soltek S et al. Low-dose gemcitabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer. Int J Cancer 2013; 133: 98–107.
38. Tongu M, Harashima N, Monma H et al. Metronomic chemotherapy with low-dose cyclophosphamide plus gemcitabine can induce anti-tumor T cell immunity in vivo. Cancer Immunol Immunother 2013; 62: 383–91.
39. Shurin GV, Tourkova IL, Kaneno R, Shurin MR. Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism. J Immunol 2009; 183: 137–44.